文献速递血脂与心血管预防

Inclisiran单药治疗无ASCVD患者的安全性与降脂疗效:VICTORION-Mono随机临床试验

Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial.
PubMed 文献 · J Am Coll Cardiol · 2025-05-05

VICTORION-Mono是一项为期6个月的多中心随机双盲3期试验,纳入350例无ASCVD、糖尿病或家族性高胆固醇血症且未接受降脂治疗的成人(LDL-C 100-190 mg/dL,10年预测ASCVD风险<7.5%),按2:1:1随机接受inclisiran、依折麦布或安慰剂。第150天LDL-C较基线变化:inclisiran -46.5%,依折麦布 -11.2%,安慰剂 1.4%;inclisiran优于安慰剂(差值-47.9%)和依折麦布(差值-35.4%),均P<0.0001,耐受性良好。

要点

  • 无ASCVD且未降脂治疗者中,inclisiran单药降LDL-C优于安慰剂与依折麦布
  • 第150天LDL-C降幅:inclisiran -46.5%,依折麦布 -11.2%,安慰剂 1.4%
  • inclisiran耐受性良好,未见新的安全性问题

核心结论

  • 在未接受降脂治疗、无ASCVD的受试者中,inclisiran单药治疗6个月降低LDL-C优于安慰剂和依折麦布,且耐受性良好。
  • 上述结果与既往在他汀治疗患者中的观察一致。

研究设计与样本

  • VICTORION-Mono(V-Mono)为6个月、随机、双盲、多中心、安慰剂及活性对照的3期试验。
  • 纳入18-75岁无既往ASCVD、糖尿病或家族性高胆固醇血症的成人,空腹LDL-C 100-190 mg/dL,10年预测ASCVD风险<7.5%,未接受任何降脂治疗。
  • 共350例随机(inclisiran 174例、依折麦布89例、安慰剂87例)并接受 assigned 治疗。
  • 研究未评估首个180天之后的每年两次inclisiran给药方案。

主要发现

  • 第150天LDL-C较基线平均百分比变化:安慰剂1.4%,依折麦布-11.2%,inclisiran-46.5%。
  • inclisiran较安慰剂的变化差值为-47.9%,较依折麦布为-35.4%(均P<0.0001)。
  • inclisiran在其他血脂及脂蛋白(a)水平上亦显示有利改善。
  • inclisiran耐受性良好,未见新的安全性问题。
  • 人群特征:女性62.6%,Black或African American 10.6%,Hispanic/Latino 39.7%;平均年龄46.1岁,平均基线LDL-C 135.4 mg/dL,平均BMI 29.8 kg/m2,10年预测ASCVD风险中位数2.2%。

关键数值与推荐

  • 主要终点为LDL-C较基线百分比变化;关键次要终点包括LDL-C绝对变化及PCSK9较基线至第150天百分比变化。
  • 第150天LDL-C较基线变化:inclisiran -46.5%,依折麦布 -11.2%,安慰剂 1.4%。
  • inclisiran vs 安慰剂的LDL-C变化差值为-47.9%,vs 依折麦布为-35.4%,均P<0.0001。

临床怎么用

  • 对于无ASCVD、未接受降脂治疗且LDL-C 100-190 mg/dL、10年ASCVD风险<7.5%的患者,inclisiran单药可作为降低LDL-C的选项。
  • 6个月随访内inclisiran降LDL-C幅度优于依折麦布和安慰剂,且耐受性良好。
  • 研究未评估180天以后的每年两次给药方案,长期用药策略需参考其他证据。

局限性

  • 研究未评估首个180天之后的每年两次inclisiran给药方案。
  • 随访仅6个月,缺乏长期心血管结局数据。
  • 纳入人群为无ASCVD、糖尿病或家族性高胆固醇血症且10年风险<7.5%者,结论不宜外推至其他人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inclisiran administration twice-yearly (after initial and 3-month doses) effectively reduces low-density lipoprotein cholesterol (LDL-C) in patients on maximally tolerated statins with atherosclerotic cardiovascular disease (ASCVD), risk equivalents, or heterozygous familial hypercholesterolemia. OBJECTIVES: In this study, the authors sought to evaluate whether inclisiran is superior as monotherapy over placebo and ezetimibe in reducing LDL-C in a primary prevention population without ASCVD. METHODS: VICTORION-Mono (V-Mono), a 6-month, randomized, double-blind, multicenter, placebo- and active-comparator controlled phase 3 trial, assessed inclisiran monotherapy in adult participants (aged 18-75 years) without prior ASCVD, diabetes, or familial hypercholesterolemia, with a fasting LDL-C of 100-190 mg/dL and 10-year predicted ASCVD risk of <7.5% according to pooled cohort equation, who were not receiving any lipid-lowering therapy. Participants were randomized (2:1:1) to inclisiran, ezetimibe, or placebo. The primary endpoint was percentage change in LDL-C from baseline, and key secondary endpoints included absolute change in LDL-C and percentage change in proprotein convertase subtilisin/kexin type 9 (PCSK9) from baseline to day 150. The study did not evaluate twice-yearly inclisiran dosing beyond the first 180 days. Safety was also assessed. RESULTS: Overall, 350 participants were randomized (n = 174, 89, and 87 to inclisiran, ezetimibe, or placebo, respectively) and received the assigned treatments. The study included a diverse population: 62.6% of participants were female, 10.6% were Black or African American, and 39.7% were Hispanic/Latino. Mean participant age was 46.1 years, mean baseline LDL-C level was 135.4 mg/dL, mean body mass index was 29.8 kg/m2, and median 10-year predicted ASCVD risk score was 2.2%. The mean percentage change in LDL-C from baseline at day 150 for placebo was 1.4%, for ezetimibe -11.2%, and inclisiran -46.5%. The difference in the change from baseline with inclisiran vs placebo was -47.9% and vs ezetimibe was -35.4% (both P < 0.0001). Inclisiran treatment also demonstrated favorable improvements in other lipid and lipoprotein(a) levels. Inclisiran was well tolerated, with no new safety concerns. CONCLUSIONS: V-Mono demonstrates for the first time that in patients not receiving lipid-lowering therapy, inclisiran as monotherapy, is superior to both placebo and ezetimibe in reducing LDL-C levels over a 6-month follow-up period and was well tolerated. These findings are consistent with previous observations in statin-treated patients. (Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy [VICTORION-Mono]; NCT05763875).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Taub PR, Gutierrez A, Wewers D, et al. Safety and Lipid-Lowering Efficacy of Inclisiran Monotherapy in Patients Without ASCVD: The VICTORION-Mono Randomized Clinical Trial. J Am Coll Cardiol. 2025. PMID: 40392667. doi:10.1016/j.jacc.2025.04.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。